NASDAQ:SNOA Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis $1.14 +0.04 (+3.64%) Closing price 04:00 PM EasternExtended Trading$1.15 +0.01 (+0.88%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sonoma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.08▼$1.1650-Day Range$1.10▼$1.3852-Week Range$0.85▼$3.95Volume36,662 shsAverage Volume42,419 shsMarket Capitalization$5.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment. The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions. Products marketed under the company’s brands have included Dermacyn, for wound and skin care, and Ocucyn, for ophthalmic care, along with veterinary products and other prescription and over-the-counter formulations. Sonoma Pharmaceuticals was formerly known as Oculus Innovative Sciences and adopted its current name in 2016. The company has served customers in the United States and international markets through a combination of direct sales, commercial partnerships and distributors.AI Generated. May Contain Errors. Read More Sonoma Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreSNOA MarketRank™: 0.757931844885 of 5 starsSonoma Pharmaceuticals scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSonoma Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSonoma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Sonoma Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sonoma Pharmaceuticals is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sonoma Pharmaceuticals is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSonoma Pharmaceuticals has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sonoma Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.30% of the float of Sonoma Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSonoma Pharmaceuticals has a short interest ratio ("days to cover") of 2.77, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sonoma Pharmaceuticals has recently decreased by 33.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSonoma Pharmaceuticals does not currently pay a dividend.Dividend GrowthSonoma Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentSonoma Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sonoma Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.02% of the stock of Sonoma Pharmaceuticals is held by insiders.Percentage Held by Institutions1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.Read more about Sonoma Pharmaceuticals' insider trading history. Receive SNOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNOA Stock News HeadlinesSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Decrease in Short InterestNovember 2 at 1:22 AM | americanbankingnews.comSonoma Pharmaceuticals Cancels Adjourned Special Stockholder MeetingAugust 19, 2026 | tipranks.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.November 3 at 1:00 AM | Digest Publishing (Ad)Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly RevenueAugust 6, 2026 | benzinga.comSonoma Pharmaceuticals Expands At-the-Market Equity Offering CapacityJune 18, 2026 | tipranks.comSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial ResultsJune 16, 2026 | finanznachrichten.deWhat's going on with Sonoma Pharma stock Monday?April 27, 2026 | msn.comSonoma Pharmaceuticals Announces Pricing of $4 Million Public OfferingApril 25, 2026 | finance.yahoo.comSee More Headlines SNOA Stock Analysis - Frequently Asked Questions How have SNOA shares performed this year? Sonoma Pharmaceuticals' stock was trading at $3.64 at the beginning of 2026. Since then, SNOA shares have decreased by 68.7% and is now trading at $1.14. How were Sonoma Pharmaceuticals' earnings last quarter? Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) posted its quarterly earnings data on Thursday, August, 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.32. The business had revenue of $6.41 million for the quarter, compared to analyst estimates of $4.99 million. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative trailing twelve-month return on equity of 21.41%. How do I buy shares of Sonoma Pharmaceuticals? Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sonoma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sonoma Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), American Airlines Group (AAL), BigBear.ai (BBAI) and GE Aerospace (GE). Company Calendar Last Earnings8/06/2026Today11/03/2026Next Earnings (Estimated)11/16/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SNOA's financial health is in the Red zone, according to TradeSmith. SNOA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SNOA CIK1367083 Webwww.sonomapharma.com Phone(800) 759-9305Fax707-283-0551Employees260Year Founded1999Profitability EPS (Trailing Twelve Months)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.17 million Net Margins-10.33% Pretax Margin-11.44% Return on Equity-21.41% Return on Assets-6.08% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.29 Sales & Book Value Annual Sales$21.92 million Price / Sales0.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book1.75Miscellaneous Outstanding Shares4,788,000Free Float4,739,000Market Cap$5.46 million OptionableNot Optionable Beta1.31 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:SNOA) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
